Health Care

Glenbrook Capital’s 30% stake in SenesTech signals confidence in its RNAi pest‑control platform, recent revenue lift, and potential medical‑device spin‑offs.

Insightful analysis of Roivant’s insider selling: understand why execs trade, what it means for investors, and how it could signal future upside or caution.

Insider buying at Rapport Therapeutics signals optimism amid a 10% drop; learn how a 0.3% stake could boost a 52‑week low stock.

Institutional investors pile into Surrozen, backing its FDA‑cleared retinal therapy and new AMD drug. 7.7% stake boosts confidence and may drive 2027‑2029 growth.

Discover how KESTRA MEDICAL’s rule‑based insider trades reveal a disciplined liquidity strategy and growing confidence in its medical technology leadership.

Dyne Therapeutics insider buy: CMO Kerr Douglas buys 8,000 shares and 12,000 RSUs, signaling long‑term optimism amid market volatility.

Merck insiders rebalancing shares—David Maraldo’s recent 401(k) filing shows a steady stake amid oncology wins and AI‑driven growth.

Insider buying signals confidence: CEO Joel L & execs buy 100k+ CHEMED options at $512.64, reflecting strong growth prospects and alignment of interests.

CEO Kevin McNamara’s latest insider purchase of 36,693 CHEMED shares signals long‑term confidence in the company’s healthcare‑diversification strategy and suggests its stock may still be undervalued.

Qiming Corporate GP VI’s 1.7 M‑share sale of Alamar Biosciences fuels a $45 M liquidity boost, offering the biotech firm a chance to fund trials, cut debt or pursue acquisitions while keeping its long‑term value intact.